Financial Review Genus achieved a solid financial performance in line with expectations in the year ended 30 June 2017, with revenue growth of 18% 6% in constant DELIVERING A SOLID currency and adjusted profit before tax up 13% 1% lower in constant currency after increased investment in R&D.
Adjusted earnings per share were also up 14% flat in constant currency.
FINANCIAL PERFORMANCE On a statutory basis, profit before tax was 33% lower, primarily due to the significant pensions-related exceptional gain in the prior year.
We continue to use adjusted results as our primary measures of financial performance as they better reflect our underlying progress.
Unless stated otherwise, this Financial Review quotes constant currency adjusted growth rates.
The effect of exchange rate movements on the translation of our overseas profits was to increase the Groups adjusted profit before tax for the year by 7.0m or 14% compared with 2016 caused by the sharp devaluation of Sterling at the end of the prior period following the UK referendum on Brexit.
Revenue Revenue increased by 18% in actual currency and 6% in constant currency to 459.1m 2016: 388.3m during the year.
In Genus PIC, growth of 7% in constant currency was across all regions but was particularly strong in Asia where revenues grew 24%.
All regions also grew royalty revenue, with particularly notable growth in GENUS ACHIEVED A Europe of 22% and Asia of 28%.
In Genus ABS, revenues grew 2% in constant currency 13% in actual SOLID FINANCIAL currency, with mixed performances across regions.
Growth was strongest PERFORMANCE IN in Latin America and IVB.
Within this, Genuss share of adjusted joint venture operating profits was higher at 7.1m 2016: 6.4m.
| 30 Genus plc Annual Report 2017 STR ATEGIC REPORT Constant 2 Actual currency currency 2017 2016 Movement Movement 1 Adjusted results m m % % Revenue 459.1 388.3 18 6 Operating profit 55.1 49.3 12 1 Operating profit incl.
JVs 60.1 54.3 11 2 Profit before tax 56.4 49.7 13 1 Basic earnings per share pence 69.4 60.7 14 2017 2016 Movement Statutory results m m % Revenue 459.1 388.3 18 Operating profit 38.2 58.6 35 Profit before tax 40.7 60.9 33 Basic earnings per share pence 53.8 81.1 34 Dividend per share pence 23.6 21.4 10 1 Adjusted results are before net IAS 41 valuation movement on biological assets, amortisation of acquired intangible assets, share-based payment expense and exceptional items.
Adjusted results are the measures used by the Board to monitor underlying performance at a Group and operating segment level.
2 Constant currency percentage movements are calculated by restating 2017 results at the average exchange rates applied in 2016.
JVs Net finance costs 3.7 4.6 20 18 Adjusted profit before tax 56.4 49.7 13 1 3 Includes share of adjusted pre-tax profits of joint ventures and removes share of profits of non-controlling interests.
Genus PIC had another robust R&D costs increased by 12%, as Exceptional Items year, with profits including joint planned, as we created our first There was a 2.5m net exceptional ventures up 7%.
Volume growth of gene edited pregnancies, ramped expense in 2017 2016: 36.3m 4% included royalty volume growth up GSS manufacturing processes, credit.
The prior year included a of 6%, helped by 45% growth in and incurred increased costs in large exceptional gain of 44.2m royalty volumes in Asia, which was our porcine nucleus herds.
related to the MPFs adoption of particularly encouraging.
Upfront CPI in place of RPI to determine sales reduced as planned.
Net Finance Costs pension increases.
In comparison, the Net finance costs reduced to 3.7m current year included an exceptional Genus ABS had a challenging year, 2016: 4.6m principally due to lower credit of 5.7m in respect of the however performance improved in IAS 19 pension interest of 1.2m 2016: arrangements for National Milk the second half as a result of actions 2.2m, following the prior years Records plc NMR exiting the MPF taken.
For the year, volumes grew 1%, agreement to change the inflation in June 2017.
There was also 5.3m while profit was 13% lower 3% lower index used to pay pensions in the MPF.
for legal fees in Genus ABSs case in actual currency, driven by weaker Average borrowings and debt interest against ST, 0.6m for acquisition performance in North America and in the year were higher, following the and integration related expenses, China and an increase in ST-produced depreciation of Sterling after the Brexit primarily fide Novo and Hermitage, inventory provisions as we prepared referendum, the Hermitage acquisition, net of a gain on the cancellation of to launch Sexcel.
Performance and the purchase of the remaining the IVB put option, and other items of improved in Europe and Latin 49% of IVB for 11.4m.
America, and IVB continued to grow.
this, the Group earned higher interest income through the year on Brazilian Real cash deposits hedging the anticipated 49% IVB acquisition.
| Genus plc Annual Report 2017 31 Financial Review continued Statutory Profit Before Tax The table below sets out a reconciliation between adjusted profit before tax and statutory profit before tax: 2017 2016 m m Adjusted profit before tax 56.4 49.7 Operating profit attributable to non-controlling interest 2.1 1.4 Net IAS 41 valuation movement on biological assets in JVs and associates 0.5 1.9 Tax on JVs and associates 1.4 1.4 Adjusting items: Net IAS 41 valuation movement on biological assets 1.1 17.1 Amortisation of acquired intangible assets 8.7 6.1 Share-based payment expense 4.6 3.8 Exceptional items 2.5 36.3 Statutory profit before tax 40.7 60.9 Our statutory profit before tax was Earnings Per Share 40.7m 2016: 60.9m, with the Adjusted basic earnings per share increased by 14% to 69.4 pence 2016: 60.7 prior year benefiting from a large pence and was unchanged in constant currency.
Basic earnings per share on a exceptional credit relating to the MPF statutory basis were 53.8 pence 2016: 81.1 pence, a decline of 34%, with the prior mentioned on page 31.
Statutory year benefiting from changing the index used for pension and deferred pension profit before tax also included a increases in the MPF from RPI to CPI.
net IAS 41 valuation biological asset movement decline of 1.1m 2016: Biological Assets 17.1m, amortisation of acquired A feature of the Groups net assets is its substantial investment in biological assets, intangibles of 8.7m 2016: 6.1m which under IAS 41 are stated at fair value.
At 30 June 2017, the carrying value of and share-based payment expense biological assets was 375.3m 2016: 354.4m, as set out in the table below: of 4.6m 2016: 3.8m.
These items 2017 2016 tend to be non-cash, can be volatile Biological assets m m and do not correlate to the underlying trading performance in the period.
Non-current assets 279.2 264.6 Current assets 73.9 66.4 Taxation Inventory 22.2 23.4 The effective rate of tax for the year, 375.3 354.4 based on adjusted profit before tax, was 25.0% 2016: 25.8% reflecting Represented by: a higher mix of profits in lower tax Porcine 215.6 184.7 jurisdictions compared with the prior Dairy and beef 159.7 169.7 year.
The effective rate remains higher 375.3 354.4 than the UK corporate tax rate due to the mix of overseas profits, particularly the proportion of profits generated in The movement in the overall carrying value of biological assets, excluding the the US and Latin America, where the effect of exchange rate translation increases of 10.9m, includes: statutory tax rates are typically between 30% and 39%, and the impact a 24.9m increase in the carrying value of porcine biological assets, due of withholding taxes on the repatriation principally to an increase in the number of animals sold on royalty contracts: and of funds to the UK.
These effects are partly mitigated by the availability of a 14.8m decrease in the carrying value of dairy and beef biological assets, manufacturing relief, R&D credits and arising from the increasing sales mix of genomic bulls which tend to have agricultural reliefs in certain shorter productive lives than proven bulls, offset partially by the assets acquired jurisdictions.
through the completion of fide Novo Genetics.
The tax rate on statutory profits was The historical cost of these assets, less depreciation, was 51.5m at 30 June 2017 18.5% 2016: 19.3% and is lower than 2016: 42.5m, which is the basis used for the adjusted results.
The historical cost the effective rate on adjusted profits depreciation of these assets included in adjusted results was 7.0m 2016: 5.5m.
primarily due to a reduction in the applicable deferred tax rate on the Retirement Benefit Obligations balance sheet carrying value of The Groups retirement benefit obligations at 30 June 2017, calculated in biological assets based on the accordance with IAS 19 and IFRIC 14, were 40.9m 2016: 44.5m before tax and anticipated mix of future sales by 32.4m 2016: 34.9m net of related deferred tax.
The largest element of this territory.
liability relates to the multi-employer MPF, where we account for this scheme on the basis of Genus being responsible for 85% of the scheme since the exit of NMR 2016: 75%.
During the year, contributions payable in respect of the Groups defined benefit schemes amounted to 7.2m 2016: 6.7m.
| 32 Genus plc Annual Report 2017 STR ATEGIC REPORT Cash Flow Free cash flow was strong at 25.4m 2016: 15.7m, driven by solid cash generated by operations of 46.3m 2016: 43.3m, representing conversion of adjusted operating profit of 55.1m 2016: 49.3m into cash of 84% 2016: 88%, and strong cash inflows from joint ventures of 8.3m 2016: 3.4m following good trading performance in our PIC joint ventures in China and Brazil.
Capital expenditure of 18.9m 2016: 18.6m included continued investment in GSS capacity and technology, research and continued investments in the Groups facilities.
The cash outflow from investments was 30.0m, primarily relating to the acquisition of fide Novo Genetics, Hermitage Genetics and the purchase of the remaining 49% of IVB.
This compares with 7.2m, net of cash acquired, from the acquisition of St Jacobs and an investment in Caribou Biosciences in 2016.
The total cash outflow for the year after these investments and dividends was 18.1m 2016: outflow 3.7m.
2017 2016 Cash flow before debt repayments m m Cash generated by operations 46.3 43.3 Interest and tax paid 11.7 13.3 Capital expenditure 18.9 18.6 Cash received from JVs 8.3 3.4 Other 1.4 0.9 Free cash flow 25.4 15.7 Acquisitions and investments 30.0 7.2 Dividends 13.5 12.2 18.1 3.7 Net Debt Net debt increased from 89.7m to 111.6m at 30 June 2017, primarily due to the 30.0m investments in fide Novo Genetics, Hermitage Genetics and the remaining 49% of IVB.
During the year, we exercised a portion of an accordion in our credit facilities to increase them by 29.2m and extended the facilities by one year to February 2022.
At the end of June 2017 there was substantial headroom of 73.6m under the extended facilities of 202.0m.
The Groups financial position and borrowing ratios remain strong with interest cover remaining at 37 times 2016: 35 times.
EBITDA as calculated under our financing facilities includes cash received from joint ventures and historical cost depreciation of biological assets.
The ratio of net debt to EBITDA on this basis moderately increased to 1.5 times 2016: 1.4 times primarily due to acquisitions and investments in the year, partially offset by increased EBITDA.
Return on Invested Capital We measure our return on invested capital on the basis of adjusted operating profit including joint ventures after tax, divided by the operating net assets of the business, stated on the basis of historical cost, excluding net debt and pension liability.
This removes the impact of IAS 41 fair value accounting, the related deferred tax and goodwill.
The return on invested capital increased to 19.9% after tax 2016: 19.1%, reflecting the increase in adjusted profit and lower tax rate in the year.
Dividend Reflecting the Boards continuing confidence in the Groups prospects, it is recommending to shareholders a final dividend of 16.2 pence per ordinary share, resulting in a total dividend for the year of 23.6 pence per ordinary share, an increase of 10% for the year.
Dividend cover by adjusted earnings remains consistently strong, at 2.9 times 2016: 2.8 times.
Stephen Wilson Group Finance Director 6 September 2017 | Genus plc Annual Report 2017 33
